Patents Examined by Grant C Currens
  • Patent number: 12036254
    Abstract: The present invention regards a composition based on bacteria belonging to the Lactobacillus paracasei species for use in the treatment and/or in the prevention of a pathological condition of the female urogenital tract, preferably a pathological condition of the female genital tract, more preferably of the vagina, said pathological condition being caused by or related with a vaginal microbiota imbalance or for treating and/or preventing the symptoms related with said pathological condition.
    Type: Grant
    Filed: October 25, 2019
    Date of Patent: July 16, 2024
    Assignee: LAC2BIOME S.R.L.
    Inventor: Andrea Biffi
  • Patent number: 11988675
    Abstract: The present disclosure provides methods, compositions and kits for measuring activity of a frataxin (FXN) protein, e.g., an FXN fusion protein. The present invention also provides methods for identifying compounds capable of modulating activity of an FXN protein, e.g., an FXN fusion protein.
    Type: Grant
    Filed: November 25, 2020
    Date of Patent: May 21, 2024
    Assignee: Larimar Therapeutics, Inc.
    Inventor: Joan David Bettoun
  • Patent number: 11969446
    Abstract: The disclosure relates generally to bacterial strains of the genus Christensenella, e.g., Christensenella sp. P152-H6d bacterial strains, and compositions comprising such bacterial strains. The disclosure further relates to methods of using such bacterial strains and compositions for preventing or treating a disorder, e.g., an inflammatory disorder, a gastrointestinal disorder, a metabolic disorder, and/or dysbiosis.
    Type: Grant
    Filed: August 28, 2020
    Date of Patent: April 30, 2024
    Assignee: XBIOME INC.
    Inventors: Peyman Akbari, Ali Akin, Rounak Feigelman, Wayne Herber, Jason Hudak, Jun Ma, Jackie Papkoff, Lauren Wong
  • Patent number: 11963989
    Abstract: The present invention discloses an application of a medical cell CMU-pb-7 in preparation of blood lipid-lowering drugs, which belongs to the technical field of biology. The medical cell CMU-pb-7 disclosed by the present invention is a newly discovered strain of Lactobacillus rhamnosus, having a collection number of CCTCC NO: M 2022220. The medical cell CMU-pb-7 of the present invention can relieve impaired glucose tolerance caused by a high-fat diet in mice with hyperlipidemia, reduce the blood lipid level, enhance the antioxidant capacity of the liver tissue, and regulate the expression of key proteins of liver lipid metabolism to relieve fatty change caused by a high-fat diet. The medical cell CMU-pb-7 disclosed by the present invention has a great potential application prospect in preparation of blood lipid-lowering drugs.
    Type: Grant
    Filed: June 17, 2023
    Date of Patent: April 23, 2024
    Assignees: GUANGDONG XINGHAI BIOTECHNOLOGY CO., LTD., GUANGDONG XINGHAI INSTITUTE OF CELL
    Inventors: Jincheng Zeng, Shaobing Zhang
  • Patent number: 11957721
    Abstract: The present invention relates to edible plant parts or tissues comprising probiotic bacteria and use thereof for oral delivery of the probiotic bacteria to an organism and enriching and/or improving the organism gastrointestinal tract microbiome. The present invention further relates to methods for selecting and/or producing probiotic bacteria capable of colonizing a plant tissue.
    Type: Grant
    Filed: April 10, 2019
    Date of Patent: April 16, 2024
    Assignees: YISSUM RESEARCH DEVELOPMENT COMPANY OF THE HEBREW UNIVERSITY OF JERUSALEM LTD., OFEK—ESHKOLOT RESEARCH AND DEVELOPMENT LTD.
    Inventors: Oded Shoseyov, Sigal Baruch-Sharon, Betty Schwartz, Lilach Iasur Kruh, Roni Almon, Alaa Naama-Amar
  • Patent number: 11944652
    Abstract: The present invention relates to vesicles derived from bacteria of the genus Sphingomonas and a use thereof. These vesicles were significantly decreased in clinical samples of patients with hepatic cirrhosis, liver cancer, myocardial infarction, renal insufficiency, diabetes, brain tumors, mild cognitive impairment, dementia, depression, autism, and atopic dermatitis as compared to normal individuals. Administration of isolated vesicles suppressed secretion of inflammatory mediators by pathogenic vesicles such as E. coli-derived vesicles. Upon oral administration, the vesicles were distributed in the brain tissue. Vesicles derived from bacteria of the genus Sphingomonas are envisioned for use in methods of diagnosis, as well as compositions and methods for treating, hepatic cirrhosis, liver cancer, myocardial infarction, renal insufficiency, diabetes, brain tumors, mild cognitive impairment, dementia, depression, autism, and atopic dermatitis.
    Type: Grant
    Filed: October 26, 2022
    Date of Patent: April 2, 2024
    Assignee: MD HEALTHCARE INC.
    Inventor: Yoon-Keun Kim
  • Patent number: 11944656
    Abstract: The invention relates to direct-fed microbials for use in E. coli, Salmonella, and/or Campylobacter inhibition in animals. More particularly, the invention relates to isolated Bacillus strains A12, 54, 681, 101, 235, and 721, and strains having all of the identifying characteristics of these strains, for a use comprising the above-mentioned use. The invention also relates to the use of isolated Bacillus strains 681,721, A12, 54, 86, 300, 101, 102, 235, and 177, and strains having all of the identifying characteristics of these strains, to prevent or reduce prolapse in an animal.
    Type: Grant
    Filed: May 1, 2019
    Date of Patent: April 2, 2024
    Assignees: MICROBIAL DISCOVERY GROUP, LLC, UNITED ANIMAL HEALTH, INC.
    Inventors: Michael R. King, Sona Son, Kyle Leistikow, Joel D. Spencer
  • Patent number: 11903971
    Abstract: Provided herein are methods and compositions for treating von Willebrand disease with platelets, platelet derivatives, and/or thrombosomes.
    Type: Grant
    Filed: February 3, 2021
    Date of Patent: February 20, 2024
    Assignee: Cellphire, Inc.
    Inventors: Keith Andrew Moskowitz, Shan Xu, William Matthew Dickerson, Amber Nicole Lee, Braden Carl Ishler, Daniel Allen Sheik
  • Patent number: 11856970
    Abstract: Described are the Bacillus subtilis strain deposited as DSM 32685 and mutant strains thereof which are susceptible to relevant antibiotics, have inhibitory activity against, for example, Staphylococcus, Streptococcus, E. coli and Salmonella, and have the ability to facilitate degradation of non-starch polysaccharides and thereby increase the amount of available oligosaccharides (sugar) in animal feed. Also described are compositions comprising at least one Bacillus subtilis strain of the disclosure and optionally further bacteria and/or one or more types of yeast and methods of using such compositions.
    Type: Grant
    Filed: January 18, 2019
    Date of Patent: January 2, 2024
    Assignee: Chr. Hansen A/S
    Inventors: Dorthe Sandvang, Ole Knudsmark Sjoeholm, Line Skjoet-Rasmussen, Jette Mundus Nielsen
  • Patent number: 11846576
    Abstract: Disclosed are a tissue staining composition and a tissue staining method using the same, wherein existing staining using hematoxylin and eosin staining reagents can be shortened from two steps to one step to reduce the reagent consumption and shorten the staining time, thereby achieving fast diagnosis.
    Type: Grant
    Filed: January 12, 2021
    Date of Patent: December 19, 2023
    Assignee: SAMSUNG LIFE PUBLIC WELFARE FOUNDATION
    Inventors: Woo Hyun Ji, Seong Il Cho, Kwang Il Kim
  • Patent number: 11833179
    Abstract: A probiotic composition comprising Bacillus amyloliquefaciens, Enterococcus faecalis, Lactobacillus salivarius, Lactobacillus johnsonii, Lactobacillus gallinarum and Lactobacillus crispatus is provided. The probiotic composition stimulates the immune response of chickens without negatively affecting growth performance. The probiotic composition can be added to poultry feed to improve the health and performance of chickens, and can be used as a replacement for antibiotic supplementation.
    Type: Grant
    Filed: October 15, 2018
    Date of Patent: December 5, 2023
    Assignee: Stellenbosch University
    Inventors: Deon Pieter Neveling, Leon Milner Theodore Dicks
  • Patent number: 11826405
    Abstract: Disclosed herein are compositions and methods for use in treating headache.
    Type: Grant
    Filed: August 28, 2020
    Date of Patent: November 28, 2023
    Assignee: Aeon Biopharma, Inc.
    Inventors: Gregory F. Brooks, Andrew M. Blumenfeld
  • Patent number: 11758924
    Abstract: The subject invention provides compositions and methods for reducing deleterious atmospheric gases and/or precursors thereof using livestock feed additives and/or supplements. In preferred embodiments, a multi-purpose composition comprising one or more beneficial microorganisms and/or one or more microbial growth by-products is applied to livestock animals' feed and/or to a field or pasture where livestock animals graze. In some embodiments, the composition controls methanogenic bacteria. In some embodiments, the composition enhances carbon sequestration in the field or pasture by promoting plant health and/or growth.
    Type: Grant
    Filed: March 30, 2020
    Date of Patent: September 19, 2023
    Assignee: LOCUS SOLUTIONS IPCO, LLC
    Inventors: Sean Farmer, Ken Alibek
  • Patent number: 11717546
    Abstract: The present invention provides a method for promoting defecation, comprising administering a composition which includes: a fermentation powder of lactic acid bacteria and a physiologically acceptable excipient, diluent, or carrier. The fermentation powder includes: a fermentation product of lactic acid bacteria, the fermentation product is obtained by incubating lactic acid bacterial strains in a culture medium containing milk, milk powders, casein, soy beans, bean products, or whey, and the lactic acid bacterial strains include: a Lactobacillus salivarius subsp. salicinius AP-32 strain, a Lactobacillus plantarum LPL28 strain, a Lactobacillus acidophilus TYCA06 strain, and a Bifidobacterium longum subsp. infantis BLI-02 strain.
    Type: Grant
    Filed: May 3, 2021
    Date of Patent: August 8, 2023
    Assignee: GLAC BIOTECH CO., LTD
    Inventors: Hsieh-Hsun Ho, Ching-Wei Chen, Yi-Wei Kuo, Yu-Fen Huang, Jui-Fen Chen, Cheng-Chi Lin
  • Patent number: 11690879
    Abstract: A bacterium belonging to a novel bacterial genus, Dysosmobacter. Also, the therapeutic, nutraceutical and cosmetic use thereof. The uses include methods for treating a disorder, promoting weight loss, decreasing food intake, increasing muscle mass, decreasing fat mass, increasing satiety, and/or decreasing weight gain associated with food intake in a subject, including administering to the subject at least one isolated bacterium belonging to the genus Dysosmobacter and/or a variant thereof and/or fragments thereof.
    Type: Grant
    Filed: July 10, 2019
    Date of Patent: July 4, 2023
    Assignee: UNIVERSITÈ CATHOLIQUE DE LOUVAIN
    Inventors: Patrice Cani, Tiphaine Le Roy
  • Patent number: 11679137
    Abstract: The present invention relates to Myoviridae bacteriophage Vib-PAP-4(Accession No. KCTC 13168BP), isolated from nature, which possesses ability to specifically kill Vibrio parahaemolyticus bacteria and has the genome represented by SEQ ID No: 1, and a method for preventing infection of Vibrio parahaemolyticus bacteria and treating infection of Vibrio parahaemolyticus baceteria, using a composition containing the bacteriophage as an effective ingredient.
    Type: Grant
    Filed: November 29, 2017
    Date of Patent: June 20, 2023
    Assignee: Intron Biotechnology, Inc.
    Inventors: Seong Jun Yoon, Soo Youn Jun, An Sung Kwon, Hyun Min Song, Soon Hye Hwang, Sang Hyeon Kang
  • Patent number: 11679138
    Abstract: The present invention relates to a Myoviridae bacteriophage Vib-PAP-7 (Accession number: KCTC 13247BP) isolated from nature, which has the ability to kill Vibrio parahaemolyticus and has the genome represented by SEQ ID NO: 1, and a method for preventing or treating a disease caused by Vibrio parahaemolyticus using a composition containing the Myoviridae bacteriophage Vib-PAP-7 as an active ingredient.
    Type: Grant
    Filed: March 8, 2018
    Date of Patent: June 20, 2023
    Assignee: Intron Biotechnology, Inc.
    Inventors: Seong Jun Yoon, Soo Youn Jun, An Sung Kwon, Hyun Min Song, Eun Ji Lee, Sang Hyeon Kang
  • Patent number: 11674870
    Abstract: A sample protection method is provided which may be used for protecting a biological sample on a microscope slide, such as during heat-induced target retrieval and/or after heat-induced target retrieval such that: 1) the sample remains adherent to the microscope slide; and 2) the microscopic morphology of the biological sample remains intact. In some embodiments, the sample protection method may include the steps of: creating a sectioned sample that is in contact with a microscope slide; applying a protecting reagent onto a sectioned sample that is in contact with a microscope slide and drying the protecting reagent in which the protecting reagent may be both applied and dried onto the sectioned sample before and/or after performing target retrieval on the sectioned sample. The protecting reagent may include a water-soluble polymer and/or a water-soluble wax, such as polyethylene glycol, polypropylene glycol, polyvinyl alcohol, polyvinylpyrrolidone, alginic acid, and carrageenan.
    Type: Grant
    Filed: January 23, 2020
    Date of Patent: June 13, 2023
    Assignees: Diagnostic BioSystems
    Inventors: Bipin Gupta, Marc Key
  • Patent number: 11660320
    Abstract: The present disclosure belongs to the technical field of biomedicine, and provides use of Faecalibacterium prausnitzii in preparation of a medicine for treating pathological ventricular remodeling and/or heart failure following myocardial infarction. The Faecalibacterium prausnitzii can improve pathological ventricular remodeling and/or heart failure caused by myocardial infarction in experimental animals, resume the systolic function, reduce the cardiac fibrosis, and inhibit the pathological myocardial hypertrophy of mice with myocardial infarction. Furthermore, the inactivated Faecalibacterium prausnitzii has no such improvement effect.
    Type: Grant
    Filed: September 30, 2021
    Date of Patent: May 30, 2023
    Assignee: Shanghai University
    Inventors: Junjie Xiao, Qiulian Zhou, Xue Pan, Danni Meng
  • Patent number: 11654166
    Abstract: The present disclosure relates to a bacteriophage composition comprising one or more (suitably two or more, or three) obligately lytic bacteriophages capable of infecting and lysing Staphylococcus aureus, and use of the same for treating Staphylococcus aureus bacterial infections.
    Type: Grant
    Filed: January 2, 2019
    Date of Patent: May 23, 2023
    Assignee: ARMATA PHARMACEUTICALS, INC.
    Inventors: Sandra P. Morales, Gillian Mearns, Deborah A. Rankin, Frenk Smrekar